nach oben

Current HIV/AIDS Reports

Erschienen in:

02.07.2021 | HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations

verfasst von: Lu Zheng, Camlin Tierney, Ronald J Bosch

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Analytical treatment interruption (ATI) remains an essential component in clinical studies investigating novel agents or combination treatment strategies aiming to induce HIV treatment-free remission or long-term viral control. We provide an overview on key study design aspects of ATI trials from the perspective of statisticians.

Recent Findings

ATI trial designs have evolved towards shorter treatment interruption phases and more frequent viral load monitoring aiming to reduce prolonged viremia risks. Criteria for ART resumption have evolved as well. Common outcome measures in modern ATI trials include time to viral rebound, viral control, and viral set point.

Summary

Design of the ATI component in HIV clinical trials is driven by the scientific question and the mechanism of action of the intervention being investigated.

Cohn LB, Chomont N, Deeks SG. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe. 2020;27:519–30.PubMedPubMedCentral

Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692–8.PubMed

Gupta RK, Peppa D, Hill AL, Gálvez C, Salgado M, Pace M, et al. Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV. 2020;7:e340–e7.PubMedPubMedCentral

• Pitman MC, Lau JSY, McMahon JH, Lewin SR. Barriers and strategies to achieve a cure for HIV. Lancet HIV. 2018;5:e317–e28 This recent review article provides a broad overview of HIV latency, methods to measure HIV persistence and experimental curative interventions being investigated in clinical trials.PubMedPubMedCentral

Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: the scale of the challenge. Nat Rev Immunol. 2019;19:45–54.PubMed

Sengupta S, Siliciano RF. Targeting the Latent Reservoir for HIV-1. Immunity. 2018;48:872–95.PubMedPubMedCentral

Sharaf RR, Li JZ. The alphabet soup of HIV reservoir markers. Curr HIV/AIDS Rep. 2017;14:72–81.PubMedPubMedCentral

Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell B, Martinez-Picado J, et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med. 2020;26:1339–50.PubMedPubMedCentral

Bruner KM, Hosmane NN, Siliciano RF. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 2015;23:192–203.PubMedPubMedCentral

10.

Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013;9(2):e1003174. https://doi.org/10.1371/journal.ppat.1003174.CrossRefPubMedPubMedCentral

11.

Li JZ, Smith DM, Mellors JW. The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS. 2015;29:1429–32.PubMed

12.

Leal L, Fehér C, Richart V, Torres B, García F. Antiretroviral therapy interruption (ATI) in HIV-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response. Vaccines. 2020;8:442.PubMedCentral

13.

•• Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. AIDS. 2019;33:773–91 This paper summarizes a systematic review of HIV clinical trials from 2000-2017 utilizing treatment interruption, describing criteria for restarting ART, monitoring and duration of treatment interruption and adverse outcomes associated with these studies.PubMed

14.

•• Jülg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019;6:e259–e68 This consensus paper provides an overview of the multitude of issues and challenges in designing and implementing a research study with analytic treatment interruption, including ethical and practical concerns.PubMedPubMedCentral

15.

Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375:2037–50.PubMedPubMedCentral

16.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JCC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535:556–60.PubMedPubMedCentral

17.

Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561:479–84.PubMedPubMedCentral

18.

Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu W-H, Fischinger S, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018;563:360–4.PubMedPubMedCentral

19.

Kutzler MA, Jacobson JM. Treatment interruption as a tool to measure changes in immunologic response to HIV-1. Curr Opin HIV AIDS. 2008;3:131–5.PubMed

20.

Stephenson KE. Therapeutic vaccination for HIV: hopes and challenges. Curr Opin HIV AIDS. 2018;13:408–15.PubMed

21.

Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ, Coombs RW, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis. 2006;194:623–32.PubMed

22.

Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. ACTG 5197: a placebo controlled trial of immunization of HIV-1 infected persons with a replication deficient Ad5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010;202:705–16.PubMed

23.

Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007;195:1426–36.PubMed

24.

Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis. 2006;194:1672–6.PubMed

25.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.

26.

Wen Y, Bar KJ, Li JZ. Lessons learned from HIV antiretroviral treatment interruption trials. Curr Opin HIV AIDS. 2018;13:416–21.PubMed

27.

Fehér C, Leal L, Plana M, Climent N, Crespo Guardo A, Martínez E, et al. Virological outcome measures during analytical treatment interruptions in chronic HIV-1-infected patients. Open Forum Infect Dis. 2019;6(12):ofz485. https://doi.org/10.1093/ofid/ofz485.

28.

Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2014;1:e13–21.PubMed

29.

Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, et al. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. J Antimicrob Chemother. 2015;70:1833–42.PubMed

30.

Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017;9(419):eaan8848. https://doi.org/10.1126/scitranslmed.aan8848.CrossRefPubMed

31.

Kroon EDMB, Ananworanich J, Pagliuzza A, Rhodes A, Phanuphak N, Trautmann L, et al. SEARCH 019 and RV254 study teams. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. J Virus Erad. 2020;6(3):100004. https://doi.org/10.1016/j.jve.2020.100004.

32.

Le CN, Britto P, Brummel SS, Hoffman RM, LI JZ, Flynn PM, et al. Time to Viral Rebound and Safety after Antiretroviral Treatment Interruption in Postpartum Women Compared to Men. AIDS. 2019;33:2149–56.PubMed

33.

Radke BR. A demonstration of interval-censored survival analysis. Prev Vet Med. 2003;59:241–56.PubMed

34.

Research C for DE and. E9(R1) Statistical Principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials [Internet]. FDA; 2021 [cited 2021 May 28]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical

35.

Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One. 2010;5(5):e10555. https://doi.org/10.1371/journal.pone.0010555.CrossRefPubMedPubMedCentral

36.

Jacobson JM, Routy J-P, Welles S, DeBenedette M, Tcherepanova I, Angel JB, et al. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016;72:31–8.PubMedPubMedCentral

37.

Tung F, Jk T, Pallikkuth S, Pahwa S, Fischl MA. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy. Vaccine. 2016;34:2225–32.PubMed

38.

Dong KL, Moodley A, Kwon DS, Ghebremichael MS, Dong M, Ismail N, et al. Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. Lancet HIV. 2018;5:e35–44.PubMed

39.

Wang R, Bing A, Wang C, Hu Y, Bosch RJ, DeGruttola V. A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption. Stat Med. 2020;39:2051–66.PubMedPubMedCentral

40.

Bing A, Hu Y, Prague M, Hill AL, Li JZ, Bosch RJ, et al. Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption. Stat Commun Infect Dis. 2020;12(Suppl 1):20190021. https://doi.org/10.1515/scid-2019-0021.

41.

Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9(3):e1003211. https://doi.org/10.1371/journal.ppat.1003211.CrossRefPubMedPubMedCentral

42.

Barouch D, Mercado N, Chandrashekar A, Borducchi E, Nkolola J, Pau M, et al. Combined active and passive immunization in SHIV-infected rhesus monkeys. Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020; Boston, MA, USA

43.

Fajnzylber J, Sharaf R, Hutchinson J, Aga E, Bosch R, Hartogensis W, et al. Frequency of posttreatment control varies by ART restart and viral load criteria. AIDS: In press; 2021.

44.

Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ, Hughes MD. The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients. AIDS Res Hum Retrovir. 2013;29:652–7.PubMedPubMedCentral

45.

•• Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016;30(3):343–53. https://doi.org/10.1097/QAD.0000000000000953. Erratum in: AIDS. 2016 Sep 10;30(14):2259. This study provides a pooled analysis of six older ATI trials, providing historical control data on ATI viral kinetics in the absence of immunologic interventions.

46.

Li JZ, Aga E, Bosch R, Pilkinton M, Kroon E, MacLaren L, et al. Time to viral rebound after interuption of modern antiretroviral therapies. In press: Clin Inf Dis. 2021

47.

Sneller MC, Huiting ED, Clarridge KE, Seamon C, Blazkova J, Justement JS, et al. Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy. J Infect Dis. 2020;222:1655–9.PubMedPubMedCentral

48.

Garner SA, Rennie S, Ananworanich J, Dube K, Margolis DM, Sugarman J, et al. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J Virus Erad. 2017;3:82–4.PubMedPubMedCentral

49.

Henderson GE, Peay HL, Kroon E, Cadigan RJ, Meagher K, Jupimai T, et al. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. J Med Ethics. 2018;44:270–6.PubMed

50.

Salantes DB, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest. 2018;128:3102–15.PubMedPubMedCentral

51.

Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, et al. Effect of short-term antiretroviral therapy interruption on levels of integrated HIV DNA. J Virol. 2018;92.

52.

Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, et al. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 2018;14(1):e1006792. https://doi.org/10.1371/journal.ppat.1006792.CrossRefPubMedPubMedCentral

53.

Colby D, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. 2018;24:923–6.PubMedPubMedCentral

54.

Lau JSY, Smith MZ, Allan B, Martinez C, Power J, Lewin SR, et al. Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. AIDS Res Ther. 2020;17:65.PubMedPubMedCentral

55.

Saberi P, Eskaf S, Sauceda J, Evans D, Dubé K. Perceptions of HIV virologic control strategies among younger and older age groups of people living with HIV in the United States: a cross-sectional survey. AIDS Res Hum Retrovir. 2020;36:606–15.PubMedPubMedCentral

56.

Coronavirus Disease (COVID-19) - events as they happen [Internet]. [cited 2021 May 17]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

57.

Fidler S, Lewin S, Deeks S, Sogaard OS, Vanderkerckhove L, Collins S, et al. HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper. J Virus Erad. 2021;7(1):100025. https://doi.org/10.1016/j.jve.2020.100025.

58.

Peluso MJ, Dee L, Shao S, Taylor J, Campbell D, Collins S, et al. Operationalizing human immunodeficiency virus cure-related trials with analytic treatment interruptions during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic: A collaborative approach. Clin Infect Dis. 2021;72(10):1843–1849. https://doi.org/10.1093/cid/ciaa1260.

59.

Kuhn L, Strehlau R, Shiau S, Patel F, Shen Y, Technau K-G, et al. Early antiretroviral treatment of infants to attain HIV remission. EClinicalMedicine. 2020;18:100241.PubMedPubMedCentral

60.

Ruel TD, Capparelli EV, Tierney C, Nelson BS, Coletti A, Bryson Y, et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV. 2021;8:e149–e57.PubMed

Titel: Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations
verfasst von: Lu Zheng
Camlin Tierney
Ronald J Bosch
Publikationsdatum: 02.07.2021
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 5/2021
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-021-00569-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Advances in the Experimental Models of HIV-Associated Neurological Disorders

Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy

A Review of Interventions to Enhance HIV Medication Adherence

Cardiovascular Disease Risk Among Transgender People with HIV

People living with HIV and the emerging field of chronic pain—what is known about epidemiology, etiology, and management

Correction to: A Review of Interventions to Enhance HIV Medication Adherence

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin